Médecins Sans Frontières, Maputo, Mozambique;
International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, New Delhi, India.
Glob Health Action. 2014 Apr 8;7:23758. doi: 10.3402/gha.v7.23758. eCollection 2014.
In Mozambique, antiretroviral therapy (ART) scale-up has been successfully implemented. However, attrition in care remains a major programmatic challenge. In 2009, an intermediary-level HIV referral center was created in Maputo to ensure access to specialized care for HIV-infected patients with complications (advanced clinical-immunological stage, Kaposi sarcoma, or suspected ART failure).
To determine the attrition from care and to identify risk factors that lead to high attrition among patients referred to an intermediary-level HIV referral center.
This was a retrospective cohort study from 2009 to 2011.
A total of 1,657 patients were enrolled, 847 (51%) were men, the mean age was 36 years (standard deviation: 11), the mean CD4 count was 27 cells/µl (interquartile range: 11-44), and one-third were severely malnourished. The main reasons for referral were advanced clinical stages (WHO stages 3 and 4, and CD4 count <50 cells/µl) in 70% of the cases, and 19% had Kaposi sarcoma. The overall attrition rate was 28.7 per 100 person-years (PYs) - the mortality rate was 5.0 (95% confidence interval [CI]: 4.2-5.9) per 100 PYs, and the loss-to-follow-up rate was 23.7 (95% CI: 21.9-25.6) per 100 PYs. There were 793 attritions - 137 deaths and 656 lost to follow-up (LTFU); 77% of all attrition happened within the first year. The factors independently associated with attrition were male sex (adjusted hazard ratio [aHR]: 1.15, 95% CI: 1.0-1.3), low body mass index (aHR: 1.51, 95% CI: 1.2-1.8), WHO clinical stage 3 or 4 (aHR: 1.30, 95% CI: 1.0-1.6; and aHR: 1.91, 95% CI: 1.4-2.5), later year of enrollment (aHR 1.61, 95% CI 1.3-1.9), and 'being already on ART' at enrollment (aHR 13.71, 95% CI 11.4-16.4).
Attrition rates among HIV-infected patients enrolled in an intermediary referral center were high, mainly related to advanced stage of clinical disease. Measures are required to address this, including innovative strategies for HIV-testing uptake, earlier ART initiation and nutritional supplementation, and special attention to men and those who are already on ART at enrolment. Qualitative research is required to understand the reasons for being LTFU and design informed evidence-based interventions.
在莫桑比克,抗逆转录病毒疗法(ART)的推广取得了成功。然而,患者流失仍然是一个主要的项目挑战。2009 年,在马普托成立了一个中级 HIV 转介中心,以确保感染 HIV 的患者(有并发症,如晚期临床-免疫阶段、卡波济肉瘤或疑似 ART 失败)能够获得专业护理。
确定从中断护理中流失的患者比例,并确定导致转介至中级 HIV 转介中心的患者高流失率的风险因素。
这是一项 2009 年至 2011 年的回顾性队列研究。
共纳入 1657 名患者,其中 847 名(51%)为男性,平均年龄为 36 岁(标准差:11),平均 CD4 计数为 27 个/µl(四分位距:11-44),三分之一的患者严重营养不良。转诊的主要原因是 70%的病例处于晚期临床阶段(世界卫生组织第 3 和第 4 阶段,和 CD4 计数<50 个/µl),19%的患者患有卡波济肉瘤。总的流失率为每 100 人年 28.7 人(每 100 人年的死亡率为 5.0(95%置信区间[CI]:4.2-5.9),失访率为 23.7(95%CI:21.9-25.6)。共有 793 人流失,其中 137 人死亡,656 人失访(LTFU);所有流失中有 77%发生在第一年。与流失相关的独立因素包括男性(调整后的危险比[aHR]:1.15,95%CI:1.0-1.3)、低体重指数(aHR:1.51,95%CI:1.2-1.8)、世界卫生组织临床阶段 3 或 4 期(aHR:1.30,95%CI:1.0-1.6;aHR:1.91,95%CI:1.4-2.5)、较晚的入组年份(aHR 1.61,95%CI 1.3-1.9)和入组时“已在接受 ART”(aHR 13.71,95%CI 11.4-16.4)。
在中级转介中心登记的 HIV 感染者的流失率较高,主要与临床疾病的晚期阶段有关。需要采取措施解决这一问题,包括创新的 HIV 检测方法、尽早开始 ART 和营养补充,并特别关注男性和入组时已在接受 ART 的患者。需要进行定性研究,以了解失访的原因,并设计基于证据的干预措施。